This inventor holds 51 USPTO granted patents and 5 published patent applications, plus 5 CIPO patents and 33 EPO patents, primarily in Immunomodulators (CPC class C07D). Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Company, Viiv Healthcare UK (No.5) Limited. Active years: 1990-2024.
Inventors with similar research interests:
Location History:
- Wallingford, CT (US) (2018)
- Meriden, CT (US) (1990 - 2024)
Company Filing History:
47 out of 3,735 
2 out of 637 
2 out of 45 Years Active: 1990-2024
Areas of Expertise:
Title: David R Langley: Pioneering Innovator with 50 Patents
Introduction:
David R Langley is a renowned inventor hailing from Meriden, CT, USA, with an impressive portfolio of 50 patents. His remarkable contributions span various areas, particularly within the field of immunomodulation. Langley's expertise and patented compounds have shown significant potential in combatting a range of diseases, including cancer and infectious diseases.
Latest Patents:
Langley's recent patents demonstrate his pioneering work in developing compounds that function as immunomodulators. These compounds have the potential to revolutionize treatment options for various diseases. Specifically, they have shown promise in enhancing the immune system's response to cancer cells and infectious agents. Langley's patents highlight his dedication to finding innovative solutions for the medical community.
Career Highlights:
Throughout his career, Langley has worked with esteemed organizations such as Bristol-Myers Squibb Company and Bristol-Myers Company. These companies are recognized leaders in the pharmaceutical industry, known for their groundbreaking research and development efforts. Langley's association with these firms underscores his commitment to driving innovation and advancing healthcare.
Collaborations:
Langley has collaborated with notable individuals in his field, including Nicholas A Meanwell and Jason T Goodrich. These collaborations likely contributed to the success of his patented compounds and their potential applications. Collaborative efforts enable inventors to pool their expertise and resources, fostering an environment that encourages breakthrough innovations. Meanwell and Goodrich, as Langley's coworkers, likely played significant roles in the development of his patented compounds.
Conclusion:
David R Langley's exceptional career path in the realm of innovations and patents showcases his unwavering dedication to scientific advancements. With an impressive 50 patents to his name, Langley is recognized as a pioneering figure in the field of immunomodulation. His patented compounds present significant potential for the treatment of diseases such as cancer and infectious diseases, providing hope for novel therapeutic approaches. As a collaborator with esteemed organizations like Bristol-Myers Squibb, Langley has cemented his position as a respected innovator and contributor to the medical community's progress.